Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-HER2 CAR T cells CCT303-406

A preparation of autologous T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) human epidermal growth factor 2 (HER2; ErbB2; HER-2), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-HER2 CAR T cells CCT303-406 target and bind to HER2-expressing tumor cells, thereby inducing selective toxicity in HER2-expressing tumor cells. HER2 is overexpressed in a variety of cancer cell types and is associated with increased tumor cell proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	CCT 303-406 CCT-303-406 CCT303-406

autologous anti-HER2 CAR T cells CCT303-406

Search NCI's Drug Dictionary